
Jassi Pannu
@JassiPannuMD
Followers
285
Following
62
Media
0
Statuses
51
Physician @StanfordDeptMed, Fellow @JHSPH_CHS
Joined March 2023
RT @EricTopol: The capability for producing "mirror life" is out there and poses danger. When some scientists who worked on this became awa….
0
163
0
RT @Nature: To prevent AI-enabled pathogen design, we need better collaboration between governments, AI developers and experts in biosafety….
nature.com
Nature - AI-enabled research might cause immense harm if it is used to design pathogens with worrying new properties. To prevent this, we need better collaboration between governments, AI...
0
31
0
RT @JanikaSchmitt: Rapid at-home tests suffer from .- chronic underinvestments.- uncertain demand.- regulatory red tape. It doesn’t have to….
0
13
0
RT @T_Inglesby: Many AI scientists, engineers, developers made voluntary commitments to build safety & security into their models -- import….
0
3
0
RT @BSPH_CHS: 🆕 in @ScienceMagazine: How can AI be governed to protect #biosecurity?. Our experts discuss evaluating advanced AI models and….
0
6
0
RT @Noahpinion: The Institute for Progress (@IFP) is the country's best think tank right now -- not yet in terms of influencing policy, but….
0
32
0
RT @JacobSwett: Some nice responses to Adam Russel's excellent piece in @ISSUESinST from @JassiPannuMD and me, @calebwatney, @stuartbuck1,….
issues.org
Readers respond to “How I Learned to Stop Worrying and Love Intelligible Failure” by Adam Russell in the Fall 2023 edition.
0
6
0
PRVs were also issued for pandemic drugs and vaccines: Covid-19 drugs like remdesivir and paxlovid, as well as a drug and vaccine for mpox.
fda.gov
21st Century Cures Act medical countermeasure (MCM)-specific provisions include Emergency Use Authorization (EUA) authority and MCM priority review vouchers (PR
1
1
1
Great summary of Priority Review Vouchers, an effective policy tool that costs the USG exactly $0, and incentivizes R&D that otherwise suffers from low profitability/market failures.
Next blog post: want to make drugs to benefit people in lower income countries, but don’t know how to finance the clinical trials?. Tell investors you’ll win a Priority Review Voucher if you succeed:
2
4
14
Always hard to deal with heavy-tail distributions, but appreciate @CGDev's effort to estimate the likelihood of COVID-19 level events
cgdev.org
Epidemics and pandemics pose a sporadic and sometimes severe threat to human health. How should policymakers prioritize preventing and preparing for such events, relative to other needs? Our simula...
1
1
8
RT @BeckerFriedman: .@UChi_MSA is looking for a Research Professional to work alongside @rglenner and Christopher Snyder to support the dev….
0
7
0
@DARPA @ARPA_H @Janika The list is by no means comprehensive, so if you have additions please reach out. We're always eager to learn more about the ARPA model - and have written about how @ARPA_H could accelerate progress in health:
ifp.org
Focusing on pandemic prevention will help the new agency achieve its ambitious goals – if it takes the right risks
0
0
4
What makes innovative agencies like @DARPA, @ARPA_H tick? How do they create entirely new technologies? My colleague @Janika has put together an incredible reading list that explores this:
ifp.org
A comprehensive syllabus on the ARPA model and its family tree
2
6
23
Thrilled to be collaborating with the inspiring @IFP team! As a society, there is so much we can do to support technologies & policies that safeguard health and prevent disease - stay tuned!.
Very excited to announce that @JassiPannuMD is joining @IFP as a Senior Biotechnology Fellow!. Jassi’s work will focus on policies and technologies that improve health and prevent disease.
1
6
31
RT @JHSPH_CHS: 🏛️Today 24 additional signatories joined CHS and 100 other stakeholders in urging US Senate and House leadership to reautho….
0
13
0